<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="treatment of HCV includes pegylated interferon-α (PEG IFN- α) plus" exact="ribavirin" post="(RBV) which has significant side effects depending upon the"/>
 <result pre="standard treatment pegylated interferon-α (PEG IFN- α) in combination with" exact="ribavirin" post="(RBV) have been employed with certain side effects and"/>
 <result pre="in different phases of clinical trials. Debio 025, a non-immunosuppressive" exact="cyclosporine" post="(Cs) analogue, is found to exhibit novel inhibition of"/>
 <result pre="STAT-C inhibitors. To date, Debio 025 was pooled with RBV," exact="VX-950" post="a protease inhibitor, 2'-C-Methylcytidine (2'-C-MeCyt) a NI and JT-16"/>
 <result pre="Combined effect of HCV-796 (an NNI of HCV NS5B) and" exact="boceprevir" post="SCH 503034 (an inhibitor of NS3 serine protease) was"/>
 <result pre="effect of HCV-796 (an NNI of HCV NS5B) and boceprevir" exact="SCH 503034" post="(an inhibitor of NS3 serine protease) was tested to"/>
 <result pre="for the clinical estimation of three-part combination of PEG IFN-α," exact="boceprevir" post="and HCV-796 [26]. Since RdRp is deficient in proof"/>
 <result pre="or β-D-2'-deoxy-2'-fluoro-2'- C-methylcytidine (2'-F-C-MeC; PSI-6130) with interferon-α 2b (IFN-α2b) plus" exact="ribavirin" post="(RBV) were assessed in subgenomic HCV relicon. β-D-2'-C-methylcytidine (2'-C-MeC;"/>
 <result pre="with interferon suggested that nitazoxanide can be exercised instead of" exact="ribavirin" post="to avoid side effect of this drug. Another newly"/>
 <result pre="and good oral exposure in rat, dogs and monkey [48]." exact="Telaprevir" post="in combination with standard antiviral therapy against HCV bestowed"/>
 <result pre="assess sustained virological response while administration of combinational therapy [49]." exact="Telaprevir" post="is the first drug against HCV presently in progress"/>
 <result pre="HCV entry [64]. These compounds alienated the D2 and D1" exact="dopamine" post="[65,66] and 5-HT2 serotonin receptors [67] in neural signaling"/>
 <result pre="trials in different phases such as BILN 2061, ITMN 191," exact="TMC 435350," post="MK 7009 (I &amp;amp; II phase) and α-ketoamide (phase"/>
 <result pre="1S385312591185 PoynardTRatziuVMcHutchisonJMannsMGoodmanZZeuzemSYounossiZAlbrechtJEffect of treatment with peginterferon or interferon alfa-2b and" exact="ribavirin" post="on steatosis in patients infected with hepatitis CHepatology200338758512829989 BurloneMEBudkowskaAHepatitis"/>
 <result pre="via clathrin-coated vesiclesJ Virol200680115711157810.1128/JVI.01717-0617005647 FeldJJHoofnagleJHMechanism of action of interferon and" exact="ribavirin" post="in treatment of hepatitis CNature200543696797210.1038/nature0408216107837 ZeuzemSFeinmanSVRasenackJHeathcoteEJLaiMYGaneEO'GradyJReichenJDiagoMLinAPeginterferon alfa-2a in patients"/>
 <result pre="dually resistant to the polymerase and protease inhibitors HCV-796 and" exact="boceprevir" post="(SCH 503034)Antimicrob Agents Chemother20095340141110.1128/AAC.01081-0818936191 LudmererSWGrahamDJBootsEMurrayEMSimcoeAMarkelEJGroblerJAFloresOAOlsenDBHazudaDJLaFeminaRLReplication fitness and NS5B drug"/>
 <result pre="BassitLGrierJBennettMSchinaziRFCombinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with" exact="ribavirin" post="in the hepatitis C virus replicon systemAntivir Chem Chemother200819253118610555"/>
 <result pre="virus polymerase that increase RNA binding can confer resistance to" exact="cyclosporine" post="AHepatology200950253310.1002/hep.2298719489073 YangWZhaoYFabryckiJHouXNieXSanchezAPhadkeADeshpandeMAgarwalAHuangMSelection of replicon variants resistant to ACH-806, a"/>
 <result pre="protease inhibitorAntimicrob Agents Chemother2009531377138510.1128/AAC.01058-0819171797 HopkinsSScorneauxBHuangZMurrayMGWringSSmitleyCHarrisRErdmannFFischerGRibeillYSCY-635, a novel nonimmunosuppressive analog of" exact="cyclosporine" post="that exhibits potent inhibition of hepatitis C virus RNA"/>
 <result pre="Chem1818541865 LawitzERodriguez-TorresMMuirAJKiefferTLMcNairLKhunvichaiAMcHutchisonJGAntiviral effects and safety of telaprevir, peginterferon alfa-2a, and" exact="ribavirin" post="for 28 days in hepatitis C patientsJ Hepatol20084916316910.1016/j.jhep.2008.03.02718486984 ShanGZPengZGLiYHLiDLiYPMengSGaoLYJiangJDLiZRA"/>
 <result pre="USA107291296 CaiGGurdalHSmithCWangHYFriedmanEInverse agonist properties of dopaminergic antagonists at the D(1A)" exact="dopamine" post="receptor: uncoupling of the D(1A) dopamine receptor from G(s)"/>
 <result pre="antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A)" exact="dopamine" post="receptor from G(s) proteinMol Pharmacol19995698999610531405 LummisSCBakerJRadioligand binding and photoaffinity"/>
 <result pre="small interference RNA library screeningJ Biol Chem2008283293617951261 RakicBSaganSMNoesthedenMBelangerSNanXEvansCLXieXSPezackiJPPeroxisome proliferator-activated receptor" exact="alpha" post="antagonism inhibits hepatitis C virus replicationChem Biol200613233010.1016/j.chembiol.2005.10.00616426968"/>
</results>
